前OpenAI科学科长 Kevin Weil 发布 Warp Sciences 药物化学学 215M美元
药物发现化学启动 Warp Sciences Inc. 发布今天以2.15亿美元的新资金，在联合创始人兼首席执行官Kevin Weil离开他的工作，在OpenAI Group PBC管理科学倡议后六个月。
Warp正在美国建立一个化学合同研究组织，为生物技术和制药公司提供其药物方案所需的分子。 铅优化模拟合成是第一个服务。 这项工作在有前途的分子上产生差异，供顾客的科学家在缩小药物候选量时进行比较。
这些物理实验的数据将训练Warp的人工智能模型，由经验丰富的化学家指导实验室进行更多的自动化工作。 TechCrunch报告，机器人将学习化学家穿着照相机和感应手套的实验室任务。
发布的Weil 称宣布，物理科学还没有从AI获得“戏剧性加速软件工程和数学”的升降机。 根据Weil，当有人制造一种化合物并进行测试时，化学和生物学进步，因此，AI的科学模型需要“规模上的现实世界数据 ”。
索尔·赖斯伯格(Sol Reisberg)，华普的联合创始人和首席科学官，曾领导过泰尔莫托生物科学股份有限公司的药用化学工作。 过去与他合作的海外化学伙伴们让他担心会保护他的节目背后的知识产权。 雇用一家美国高级合同研究公司意味着支付他所谓的“价格溢价 ”。 Warp旨在与那些来自美国实验室的海外合作伙伴的口径相匹配，其价格没有加价。
很多海外工作都发生在中国据路透社称，在2024年接受生物技术创新组织调查的124家生物技术公司中，74%的公司与中国公司签订了临床前和临床服务合同。 目前，《生物和生态安全法》限制联邦合同和涉及指定“生物技术公司”的赠款。 唐纳德·特朗普总统于12月将其签署为法律。
作为承包商，Warp只制造其客户选择的分子。 称联合创始人兼首席操作官DJ Patil。
帕蒂尔在担任白宫第一位首席数据科学家后，是德沃特德健康公司的创始执行官。 第四位联合创始人，首席技术官马诺·帕卢里(Mano Paluri)是Meta平台股份有限公司在成为Meta超级智能实验室副总裁前数年创办AI研究组的团队成员。
Lightspeed Venture Partners LP领导了资金回合。 其他18家参与公司包括机构风险伙伴LP、Lux Capital Management和Menlo Ventures LP. Coinbase Global Inc.首席执行官Brian Armstrong和OpenAI首席财务官Sarah Friar作为个人投资，其他11个天使投资者也是如此。
图片：SiliconANGLE/GPT 图像：2.5
SiliconANGLE联合创始人John Furrier的留言：
支持我们的使命，通过与CUBE社区接触，保持内容的开放和自由。 加入CUBE的校友信托网络，其中技术领导者相互连接，分享情报，创造机会。
- 15M+观看CUBE视频，为AI、云层、网络安全等各种对话提供动力
- 11.4k+CUBE校友——通过独特的信任网络与11400多名技术和企业领袖建立联系，塑造未来
你是AWS客户吗？在财务上支持SiliconANGLE，从我们的市场门户页面和链接购买您的AWS服务：https://siliconangle.com/aws-marketplace/.
关于 SiliconANGLE 媒体
SiliconANGLE Media由技术视觉家约翰·弗瑞尔(John Furrier)和戴夫·韦兰特(Dave Vellante)创立，构建了产业领先数字媒体品牌的动态生态系统，达到1500+百万精英技术专业人士。 利用CUBEAi.com神经网络，帮助科技公司以数据为导向做出决策
本文由 AI图鉴自动抓取并翻译，版权归原作者所有；如需查看原文请点下方链接。
Ex-OpenAI science chief Kevin Weil launches Warp Sciences with $215M for drug chemistry
Drug discovery chemistry startup Warp Sciences Inc. launched today with $215 million in new funding, six months after co-founder and Chief Executive Kevin Weil left his job running science initiatives at OpenAI Group PBC.
Warp is building a chemistry contract research organization in the U.S. to supply biotech and pharmaceutical companies with the molecules their drug programs need. Lead optimization analog synthesis is the first service. That work produces variations on a promising molecule for the customer’s scientists to compare as they narrow in on a drug candidate.
Data from those physical experiments will train Warp’s artificial intelligence models, with experienced chemists guiding the work as the lab takes on more automation. Robots will learn lab tasks from chemists wearing cameras and sensor gloves, TechCrunch reported.
Weil said in the launch announcement that the physical sciences have yet to get the lift from AI that has “dramatically accelerated software engineering and mathematics.” Chemistry and biology advance when someone makes a compound and tests it, according to Weil, so AI models for science need “real-world data at scale.”
Sol Reisberg, Warp’s co-founder and chief scientific officer, previously led medicinal chemistry work at Terremoto Biosciences Inc. Overseas chemistry partners he worked with in the past left him worried about protecting the intellectual property behind his programs. Hiring a boutique U.S. contract research firm instead means paying what he called a “price premium.” Warp aims to match the caliber of those overseas partners from labs in the U.S., at prices that leave the markup out.
A lot of that overseas work ends up in China. Contracts with Chinese companies for preclinical and clinical services were in place at 74% of the 124 biotech companies the Biotechnology Innovation Organization surveyed in 2024, according to Reuters. The BIOSECURE Act now restricts federal contracts and grants involving designated “biotechnology companies of concern.” President Donald Trump signed it into law in December.
As a contractor, Warp makes only the molecules its customers choose. “We’re not developing drugs of our own,” said co-founder and Chief Operating Officer DJ Patil.
Patil was a founding executive at Devoted Health Inc. after serving as the White House’s first chief data scientist. The fourth co-founder, Chief Technology Officer Mano Paluri, was part of the team that started Meta Platforms Inc.’s AI research group years before he became a vice president at Meta Superintelligence Labs.
Lightspeed Venture Partners LP led the funding round. The 18 other participating firms include Institutional Venture Partners LP, Lux Capital Management and Menlo Ventures LP. Coinbase Global Inc. Chief Executive Brian Armstrong and OpenAI Chief Financial Officer Sarah Friar invested as individuals, as did 11 other angel investors.
Image: SiliconANGLE/GPT Image 2.5
A message from John Furrier, co-founder of SiliconANGLE:
Support our mission to keep content open and free by engaging with theCUBE community. Join theCUBE’s Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities.
- 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more
- 11.4k+ theCUBE alumni — Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network
Are you an AWS customer? Support SiliconANGLE financially by buying your AWS services from our Marketplace portal page and links: https://siliconangle.com/aws-marketplace/
About SiliconANGLE Media
Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Our new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations.
Auto-fetched and translated by AI Atlas. All rights belong to the original author.